PT Asuransi Jasa Tania Tbk (ASJT) Stock Analysis 2026: Is This Indonesian Insurance Stock Undervalued?
 |
| PT Asuransi Jasa Tania Tbk (ASJT) Stock Analysis |
Worldreview1989 - PT Asuransi Jasa Tania Tbk (IDX: ASJT) is a small-cap Indonesian general insurance company that offers an unusual combination for investors: a stock trading below book value, a historically profitable underwriting business, and strong insurance-sector capital metrics—but also very low returns on equity and a sharp deterioration in earnings during the first quarter of 2026.
For American investors accustomed to analyzing insurers such as Progressive, Travelers, Chubb, or Allstate, ASJT is interesting precisely because it is not a conventional high-growth insurance stock. The investment case depends much more on book value, underwriting discipline, capital strength, and the company's ability to restore profitability.
Important: ASJT has very limited English-language coverage among U.S. retail investors. Therefore, the “American reader review” perspective below does not use fabricated quotations. Instead, it applies the questions and investment criteria commonly emphasized by U.S. investors when evaluating insurance companies.
ASJT Stock Snapshot
| Metric | Latest / 2025 Data |
|---|---|
| Ticker | ASJT |
| Company | PT Asuransi Jasa Tania Tbk |
| Sector | General Insurance |
| Shares outstanding | 1.40 billion |
| Share price* | Rp160 |
| Approx. market capitalization | Rp224 billion |
| 2025 revenue | Rp222.54 billion |
| 2025 net profit | Rp6.70 billion |
| 2025 EPS | Rp4.79 |
| 2025 book value/share | Rp229.74 |
| Approx. P/B at Rp160 | 0.70x |
| Approx. P/E at Rp160 | 33.4x |
| 2025 ROE | 2.08% |
| 2025 ROA | 1.20% |
| 2025 dividend/share | Rp0.9574 |
| Approx. dividend yield at Rp160 | 0.60% |
| Q1 2026 net profit | -Rp9.05 billion |
*The Rp160 reference is the August 28, 2026 closing price reported by Investing.com. (Investing.com Indonesia)
The 2025 financial statements were audited, while the March 2026 interim statements are unaudited. The company publishes its financial reports and annual reports through its investor-relations website. (Jasa Tania)
What Does PT Asuransi Jasa Tania Actually Do?
PT Asuransi Jasa Tania Tbk is a general insurance company rather than a life insurer. Its business includes areas such as:
property insurance,
motor vehicle insurance,
marine cargo,
marine hull,
engineering insurance,
liability insurance,
personal accident,
surety bonds,
miscellaneous insurance, and
health-related coverage.
This diversification matters because an insurer's profitability can vary significantly between business lines.
The company's 2026 first-quarter results demonstrate this clearly. Property and engineering produced positive insurance-service results, while motor vehicles, personal accident, bonds and health generated negative results.
The American Investor Perspective: What Would U.S. Readers Ask?
An American investor looking at ASJT would probably ask five questions:
Is the insurer financially safe?
Is underwriting profitable?
Is book value actually growing?
Is the stock cheap because the market is overlooking it—or because returns are poor?
Can management turn the recent earnings decline around?
These questions are more important than simply asking whether ASJT's stock price looks cheap.
1. Revenue Grew, But Profitability Weakened
ASJT generated approximately Rp222.54 billion in insurance-service revenue in 2025, compared with Rp213.16 billion in 2024.
That represents approximately 4.4% year-over-year growth.
However, insurance-service expenses increased much faster, reaching approximately Rp104.91 billion, compared with Rp87.82 billion in 2024.
That is approximately 19.5% growth in insurance-service expenses.
The result was a higher insurance-service result of about Rp70.53 billion, up from Rp64.01 billion, but after operating expenses, other expenses and taxes, net profit declined.
ASJT reported:
2025 net profit: Rp6.70 billion
2024 net profit: Rp7.49 billion
Net profit decline: approximately 10.5%
The audited financial statements show the underlying numbers. (Indo Premier)
Why this matters
This is an important distinction for insurance investors.
A company can increase premiums while simultaneously becoming less attractive if claims and operating costs grow too quickly.
In other words:
Premium growth ≠ shareholder value creation.
The more important question is whether ASJT can convert premium growth into sustainable underwriting profit and ultimately higher ROE.
2. ASJT's Biggest Problem: Low ROE
At first glance, ASJT looks inexpensive.
With a share price around Rp160 and 2025 book value per share of approximately Rp229.74, the stock trades at only about:
0.70x Price-to-Book Value
That looks attractive.
But American insurance investors generally understand that a low P/B multiple is not automatically a bargain.
The market may assign a discount to book value because the company is not generating a sufficiently high return on that capital.
ASJT's 2025:
ROE: approximately 2.08%
ROA: approximately 1.20%
For comparison, a company generating only 2% ROE has a difficult time justifying a premium valuation.
This produces one of the most important conclusions in the ASJT investment case:
ASJT is cheap on book value but not cheap on earnings.
At Rp160:
P/B ≈ 0.70x
P/E ≈ 33.4x
The P/E calculation is based on 2025 EPS of approximately Rp4.79.
Therefore, investors buying ASJT are effectively betting on future earnings recovery, rather than buying a rapidly growing earnings machine.
3. Book Value Is ASJT's Strongest Valuation Argument
Insurance companies are different from many industrial companies because shareholder equity is particularly important.
ASJT ended 2025 with approximately:
Total equity: Rp321.64 billion
With 1.4 billion shares outstanding, that translates into approximately:
Book value per share = Rp229.74
At Rp160, investors are paying roughly 70% of book value.
That provides a margin of safety if the book value is maintained and the company can eventually generate better returns on equity.
However, investors should not assume that book value is automatically worth Rp229.74 per share.
Book value becomes significantly more valuable when the insurer can earn an attractive ROE.
4. Q1 2026 Was a Major Warning Signal
This is probably the most important issue for investors today.
ASJT's first-quarter 2026 results were significantly weaker than the same period in 2025.
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Insurance-service revenue | Rp54.00B | Rp53.61B |
| Insurance-service expense | Rp84.12B | Rp29.50B |
| Reinsurance contract result | Rp36.19B | -Rp11.04B |
| Net insurance-service result | Rp6.08B | Rp13.08B |
| Net investment income | Rp2.25B | Rp2.26B |
| Operating expenses | Rp17.09B | Rp17.05B |
| Net income | -Rp9.05B | -Rp2.47B |
| EPS | -Rp6.46 | -Rp1.76 |
The March 2026 financial statement shows that the deterioration was driven primarily by the insurance business rather than investment income or operating expenses.
This is a major red flag.
5. Claims and Underwriting Need to Be Watched Closely
The Q1 2026 numbers reveal a striking increase in insurance-service expenses.
Insurance-service revenue was approximately Rp54.0 billion, but insurance-service expenses reached Rp84.1 billion.
The company recovered part of this pressure through reinsurance, resulting in a positive reinsurance-contract contribution of approximately Rp36.2 billion.
Nevertheless, the net insurance-service result declined to Rp6.08 billion from Rp13.08 billion.
The business-line data are even more revealing.
Positive contributors in Q1 2026
Property: approximately +Rp9.21 billion
Engineering: approximately +Rp7.65 billion
Marine cargo: approximately +Rp2.92 billion
Miscellaneous: approximately +Rp2.37 billion
Negative contributors
Personal accident: approximately -Rp3.77 billion
Motor vehicles: approximately -Rp1.66 billion
Bonds: approximately -Rp1.54 billion
Health: approximately -Rp0.48 billion
These figures come directly from the Q1 2026 financial statement notes.
American investor interpretation
This does not necessarily mean ASJT's business model is broken.
It means investors need to determine whether Q1 represents:
A. temporary claims volatility, or
B. a structural deterioration in underwriting quality.
That distinction could determine whether ASJT is an opportunity or a value trap.
6. Investment Income Is Not the Problem
ASJT generated approximately Rp2.25 billion in net investment income during Q1 2026, compared with Rp2.26 billion in Q1 2025.
That is essentially flat.
This is important because insurers typically invest their capital and insurance float.
In ASJT's case, the recent earnings problem is therefore not primarily caused by investment income collapsing.
Instead, the pressure is coming from insurance-service profitability.
This makes the recovery thesis relatively straightforward:
ASJT needs underwriting improvement more than it needs aggressive investment gains.
That is generally a healthier turnaround thesis because investment income can be volatile, whereas sustainable underwriting profitability is fundamental to an insurance company's business model.
7. Balance Sheet: Still Relatively Strong
At March 31, 2026, ASJT reported:
Total assets: approximately Rp543.26 billion
Total liabilities: approximately Rp233.96 billion
Total equity: approximately Rp309.30 billion
Compared with December 2025, equity declined from Rp321.64 billion to Rp309.30 billion.
The decline is important because the company incurred a Q1 net loss of Rp9.05 billion and also recorded other comprehensive losses.
Nevertheless, equity remains substantially larger than the company's market capitalization at around Rp224 billion based on a Rp160 share price.
That is the core reason ASJT can appear interesting to value investors.
8. ASJT Has a Very Low Dividend Yield
ASJT's 2025 dividend was approximately:
Rp0.9574 per share
KSEI records the dividend distribution at Rp0.9574 per ASJT share, with distribution on May 26, 2026. (KSEI)
At a Rp160 share price:
Dividend yield ≈ 0.60%
This is not particularly attractive for an income investor.
Therefore, ASJT should not primarily be viewed as a dividend stock.
The potential investment thesis is more about:
undervaluation relative to book value,
earnings recovery,
improved underwriting,
capital efficiency, and
possible re-rating of the P/B multiple.
9. ASJT's Historical Rights Issue Is Important
ASJT previously expanded its share capital through a rights issue.
The company issued 800 million new shares, increasing issued and paid-up shares from 600 million to 1.4 billion. The offering price was Rp125 per share. (Emitten Announcement)
This history matters because investors need to distinguish between:
capital growth and per-share value creation.
Increasing capital can strengthen an insurer's solvency and support business expansion, but it also increases the number of shares over which future profits must be distributed.
The company reported that by June 2026, approximately 99.19% of the proceeds from the HMETD had been realized, leaving about Rp796.77 million. (BCA Sekuritas)
For investors, the question is whether the additional capital ultimately produces higher underwriting profit and ROE.
10. Regulatory Capital Is a Key Strength
Insurance companies should not be analyzed like ordinary industrial companies.
Capital adequacy and liquidity are critical.
OJK's regulatory framework sets minimum financial-health requirements for Indonesian insurers, and OJK's newer rules also address asset-liability management and investment management for insurers and reinsurers. (OJK Portal)
ASJT has historically reported a substantial capital buffer, which is one reason the company can potentially absorb periods of higher claims.
However, investors should continue monitoring:
RBC,
liquidity ratio,
investment adequacy,
claims ratio,
combined ratio,
reinsurance exposure,
insurance contract liabilities, and
equity.
For an insurer, these metrics can be more informative than conventional debt ratios.
11. What Would American Investors Like About ASJT?
Based on the investment criteria commonly used by U.S. retail and value investors, there are several attractive characteristics.
1. Trading below book value
At approximately 0.70x 2025 book value, the stock has a clear asset-value argument.
2. Established insurance operation
ASJT is not a startup insurer trying to establish a customer base.
3. Diversified insurance products
The company operates across property, engineering, marine, motor vehicle, bonds and other insurance segments.
4. Investment portfolio provides additional income
Investment income contributes to profitability and provides another earnings source.
5. Potential earnings recovery
The stock could rerate significantly if the company restores sustainable profitability.
What Would American Investors Dislike?
There are equally important concerns.
1. Very low ROE
A 2.08% ROE is weak.
2. High P/E despite low profitability
At approximately 33x 2025 earnings at Rp160, ASJT is not cheap based on earnings.
3. Q1 2026 loss
The company lost Rp9.05 billion in Q1 2026.
4. Limited liquidity
ASJT is a small-cap Indonesian stock with much lower trading liquidity than major Indonesian insurers and banks.
5. Low dividend yield
Around 0.6% does not provide much income support.
6. Underwriting volatility
The Q1 2026 numbers demonstrate how quickly insurance-service profitability can change.
ASJT Valuation: Cheap or Value Trap?
This is where the analysis becomes interesting.
At Rp160:
Book-value approach
2025 BVPS ≈ Rp229.74
Therefore:
Rp160 / Rp229.74 ≈ 0.70x P/B
That is objectively inexpensive relative to book value.
But:
Earnings approach
2025 EPS ≈ Rp4.79
Therefore:
Rp160 / Rp4.79 ≈ 33.4x P/E
That is not inexpensive.
This creates a contradiction:
ASJT looks cheap as an asset but expensive as an earnings-producing business.
The market appears to be saying that ASJT's book value is worth something, but the company currently does not generate enough profit from that capital to deserve a high valuation.
ASJT Scenario Analysis
Rather than giving a false precision price target, it is more useful to establish scenarios.
| Scenario | Potential interpretation |
|---|---|
| Bear case | Underwriting weakness persists, book value declines and P/B remains below 0.7x |
| Base case | Earnings stabilize, book value remains around current levels and stock trades around 0.7–0.85x P/B |
| Bull case | Underwriting recovers, ROE improves materially and market rerates ASJT toward 0.9–1.0x P/B |
Using the 2025 book value of approximately Rp229.74/share:
0.7x P/B ≈ Rp161
0.8x P/B ≈ Rp184
0.9x P/B ≈ Rp207
1.0x P/B ≈ Rp230
These are valuation scenarios, not price targets.
The most important variable is not whether ASJT can reach book value.
It is whether the company can improve ROE enough to justify a higher percentage of book value.
The Most Important Catalyst: ROE Recovery
For ASJT, I would watch ROE more closely than revenue growth.
Imagine ASJT eventually produces:
ROE above 5% → meaningful improvement
ROE around 8% → much stronger investment case
ROE above 10% → potentially deserving of a substantially higher P/B multiple
The market could then begin viewing ASJT differently.
Instead of:
“A small insurer trading below book value.”
the narrative could become:
“A profitable insurer trading below book value with improving capital efficiency.”
That is a much stronger investment story.
What Should Investors Watch in the Next Financial Reports?
For the remainder of 2026, investors should monitor these seven indicators:
1. Net insurance-service result
This should recover from the Q1 weakness.
2. Claims development
A sustained increase in claims would be a major negative.
3. Combined ratio
A lower combined ratio generally indicates better underwriting efficiency.
4. ROE
This is perhaps the most important long-term valuation metric.
5. Book value per share
Investors should determine whether equity continues to compound.
6. Investment income
Stable investment income can provide an earnings cushion.
7. RBC and liquidity
These remain essential indicators of insurance-sector financial health.
ASJT's official website publishes monthly, quarterly and semester financial information, including the June 2026 report. (Jasa Tania)
Final Verdict: Is ASJT Stock Worth Buying?
My assessment: SPECULATIVE / WATCHLIST
ASJT is not an obvious “buy” simply because it trades below book value.
The company has a potentially attractive asset valuation, but its profitability is currently too weak to make the valuation thesis straightforward.
Bullish factors
+ Approximately 0.70x P/B
+ Established insurance business
+ Positive historical profitability
+ Diversified insurance portfolio
+ Investment income contribution
+ Potential for earnings recovery
+ Significant book value relative to market capitalization
Bearish factors
− Q1 2026 net loss of Rp9.05 billion
− ROE only around 2.08% in 2025
− 2025 net profit declined approximately 10.5%
− P/E around 33x based on 2025 earnings
− Very low dividend yield
− Small-cap and relatively illiquid
− Underwriting profitability needs improvement
Bottom line
For a value investor, ASJT is interesting because the market price is below book value.
For an income investor, ASJT is not particularly compelling because the dividend yield is low.
For a growth investor, ASJT currently lacks sufficient earnings growth and ROE.
For a special-situation investor, however, ASJT could become interesting if the company demonstrates that the Q1 2026 loss was temporary and underwriting profitability returns.
The key investment thesis can therefore be summarized in one sentence:
ASJT is potentially undervalued on book value, but the discount is justified unless management can turn that capital into substantially higher returns.
The next several financial reports will be crucial. If ASJT returns to consistent profitability while maintaining book value, a re-rating from roughly 0.7x P/B toward 0.8–1.0x P/B becomes plausible. If losses continue, the low P/B ratio may simply represent a market discount for chronically weak returns.
For U.S. readers: ASJT should be treated as a high-risk Indonesian small-cap insurance/value situation rather than as a direct substitute for established U.S. insurers such as Chubb, Travelers, Progressive, or Allstate.
Primary & Credible Sources
PT Asuransi Jasa Tania — Annual Reports — official investor-relations source for annual and sustainability reports. (Jasa Tania)
PT Asuransi Jasa Tania — Financial Reports — official source for semester financial reports, including June 2026. (Jasa Tania)
Otoritas Jasa Keuangan (OJK) — Indonesian financial-services regulator and primary regulatory source. (OJK Portal)
KSEI — ASJT Corporate Actions — official securities depository record for ASJT corporate actions and dividends. (KSEI)
Audited 2025 Financial Statements: issuer financial statements audited for the year ended December 31, 2025. (Indo Premier)
Q1 2026 Financial Statements: issuer interim financial statements for the period ended March 31, 2026.
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group